Senior Translational Fellow, Center for Developmental Therapeutics and Research Professor, Department of Chemistry; Weinberg College of Arts and Sciences
Jack Henkin has carried out and led biomedical research for over 30 years, more than 25 years being in drug discovery at Abbott Laboratories where he was named outstanding researcher of the year 2003 for advancing novel clinical development candidates to treat thrombosis, cancer and neovascular disease, and for pioneering safe novel targeted agents to treat cancer in pet dogs.
These continue in veterinary development. His biochemical expertise includes enzyme mechanism, the design of enzyme inhibitors, and the use of fluorescence and UV-Vis spectroscopy and of photo-affinity labeling to study macromolecule structure and interactions. He has bridged between discovery and early clinical development of new drug entities including recombinant proteins and bioactive peptides that reached phase II clinical studies. His recent research led to successful in vivo tumor-specific delivery of toxins and siRNA as cargo within ligand and antibody-directed nanoparticles.
Dr. Henkin has innovated in the area of angiogenesis where he has been awarded many patents for discovering new agents designed to block tumor angiogenesis. This now drives his current research which is focused on ameliorating neovascular diseases of the retina and of the female reproductive system, including macular degeneration, endometriosis and ovarian cancer.
Office: Silverman Hall 1587
j-henkin [at] northwestern [dot] edu